News

Bharat Parenterals Limited has issued a corrigendum to the notice of its Extraordinary General Meeting (EGM) scheduled for October 23, 2026, following a direction from the BSE Limited. The corrigendum, pertaining to Item No. 1 concerning a proposed preferential issue of equity shares, includes additional disclosures regarding the appointment of Crisil Ratings Limited as a monitoring agency, as required by Securities and Exchange Board of India (SEBI) regulations due to the issue size exceeding Rs 100 crore.

Bharat Parenterals Limited, in compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, confirmed that securities received from depository participants for dematerialization during the quarter ended September 30, 2026, were accepted or rejected by Adroit Corporate Services Private Limited, the company’s registrar and share transfer agent, and that the securities have been listed on stock exchanges.

Bharat Parenterals Limited informed the BSE Limited that the trading window for dealing in the company`s equity shares will be closed from October 1, 2026, until 48 hours after the declaration of unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2026.

Bharat Parenterals Limited will hold a board meeting on Tuesday, September 29, 2026, to consider and evaluate a proposal for the issuance of equity shares or other eligible securities via a preferential issue, according to a regulatory filing with the BSE Limited. The company’s trading window will be closed from September 24, 2026, until 48 hours after the conclusion of the meeting, as per its code of conduct for regulating trading by designated persons.

Bharat Parenterals Limited has set Saturday, September 12, 2026, as the record date for determining entitlement to receive a dividend for the financial year 2025-26, subject to approval by members at the annual general meeting scheduled for 2026.